Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 5/20 | 0.49 |
| ▸ | CTSL | P07711 | 4/20 | 0.49 |
| ▸ | CTSS | P25774 | 4/20 | 0.49 |
| ▸ | CTSB | P07858 | 3/20 | 0.49 |
| ▸ | ELANE | P08246 | 2/20 | 0.49 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | PRTN3 | P24158 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | SYK | P43405 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2402783 | 0.87 | CTRB1 (0.58) | CTSKCTSLCTSSCTSBELANE | |
| SCHEMBL12798890 | 0.77 | ATM (0.57) | CTSKCTSLCTSSCTSBELANE | |
| SCHEMBL13489691 | 0.77 | ATM (0.57) | CTSKCTSLCTSSCTSBELANE | |
| SCHEMBL6407665 | 0.77 | ATM (0.59) | CTSKCTSLCTSSCTSBELANE | |
| SCHEMBL13572927 | 0.77 | ATM (0.59) | CTSKCTSLCTSSCTSBELANE | |
| SCHEMBL14999596 | 0.77 | ATM (0.59) | CTSKCTSLCTSSCTSBELANE | |
| SCHEMBL3911384 | 0.75 | SYK (0.70) | CTSKCTSLCTSSCTSBCTRB1 | |
| SCHEMBL14704026 | 0.75 | ATM (0.61) | CTSKCTSLCTSSCTSBELANE | |
| SCHEMBL12906609 | 0.75 | ATM (0.61) | CTSKCTSLCTSSCTSBELANE | |
| SCHEMBL12220545 | 0.75 | SYK (0.69) | CTSKCTSLCTSSCTSBELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9145415-B2 | Nitrogen-containing heterocyclic compound or salt thereof | FUJIFILM CORPORATION (JP) | 2015-09-29 | — | — | US | disclosed |
| US-20150045339-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2015-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150045339-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF | FLT3, NPM1, ABL1 | CTSK 2756/4885CTSL 2648/4885CTSS 3922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.